MBMA vs. Meta-Analysis: Quick Comparison Guide
Discover how Model-Based Meta-Analysis (MBMA) outperforms traditional meta-analysis in drug development by predicting outcomes, informing…
Certara2025 年 10 月 8 日
C-QTc and C-QT Analysis: Replacing TQT Studies and Accelerating Cardiovascular Safety Decisions
Replace or waive TQT studies with validated C-QT analysis strategies accepted by FDA, EMA, PMDA.…
Certara2025 年 10 月 3 日
Certara & Dizal Partner to Fast-Track FDA Approval of Sunvozertinib for Lung Cancer
Certara’s support enabled fast-track FDA oncology approval 2025 for Sunvozertinib, a breakthrough NSCLC therapy targeting…
Certara2025 年 10 月 2 日
Certara Launches Libra™: AI-Powered Drug-Induced Liver Injury Prediction Tool
RADNOR, Pa. – 2025 年 9 月 17 日 – Certara, Inc. （纳斯达克股票代码：CERT), a global leader in…
Certara2025 年 9 月 17 日
Top 10 Things to Know About ADNCA for Non-Compartmental Analysis
Learn how to transition from non-standard ADPC datasets to the CDISC ADNCA ADaM standard. Improve…
Certara2025 年 9 月 11 日
